FTC Challenges Patents on 20 Brand-Name Drugs as Chair Accuses Them of Inflating Prices with 'Bogus' Patents from lead list providers Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
⏲ Duration: 0:34 👁 View: 1.3M times ✓ Published: 02-May-2024
Description: The Federal Trade Commission challenges patents on 20 brand-name drugs to spur competition, including the blockbuster weight-loss drug Ozempic. The FTC sent warning letters to 10 drugmakers alleging certain patents are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and block cheaper generics. FTC Chair Lina Khan said drug companies use \